Arrowstreet Capital Limited Partnership bought a new position in Sanofi (NYSE:SNY) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 56,400 shares of the company’s stock, valued at approximately $2,702,000.
Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Pennsylvania Trust Co lifted its stake in shares of Sanofi by 0.4% in the second quarter. Pennsylvania Trust Co now owns 8,314 shares of the company’s stock worth $402,000 after buying an additional 37 shares in the last quarter. Moors & Cabot Inc. lifted its position in Sanofi by 0.7% during the second quarter. Moors & Cabot Inc. now owns 6,494 shares of the company’s stock valued at $311,000 after purchasing an additional 43 shares during the period. Rehmann Capital Advisory Group lifted its position in Sanofi by 0.7% during the second quarter. Rehmann Capital Advisory Group now owns 7,235 shares of the company’s stock valued at $347,000 after purchasing an additional 47 shares during the period. Strategic Global Advisors LLC lifted its position in Sanofi by 0.6% during the second quarter. Strategic Global Advisors LLC now owns 8,632 shares of the company’s stock valued at $414,000 after purchasing an additional 54 shares during the period. Finally, Financial Advisors Network Inc. lifted its position in Sanofi by 1.0% during the first quarter. Financial Advisors Network Inc. now owns 8,282 shares of the company’s stock valued at $409,000 after purchasing an additional 84 shares during the period. Hedge funds and other institutional investors own 9.35% of the company’s stock.
In related news, major shareholder Sanofi acquired 105,820 shares of the company’s stock in a transaction that occurred on Thursday, August 24th. The stock was purchased at an average price of $482.04 per share, for a total transaction of $51,009,472.80. The purchase was disclosed in a document filed with the SEC, which is available at this link. Company insiders own 1.00% of the company’s stock.
WARNING: This report was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this report on another domain, it was illegally copied and reposted in violation of US & international trademark & copyright legislation. The legal version of this report can be accessed at https://www.dispatchtribunal.com/2017/10/28/arrowstreet-capital-limited-partnership-acquires-new-position-in-sanofi-sny.html.
Shares of Sanofi (SNY) traded down 0.02% during mid-day trading on Friday, hitting $47.53. 2,367,326 shares of the stock were exchanged. Sanofi has a 52-week low of $37.25 and a 52-week high of $50.65. The company has a market cap of $119.37 billion, a P/E ratio of 11.04 and a beta of 0.87. The stock’s 50-day moving average price is $49.49 and its 200-day moving average price is $48.40.
Sanofi (NYSE:SNY) last posted its quarterly earnings data on Monday, July 31st. The company reported $0.74 EPS for the quarter, hitting analysts’ consensus estimates of $0.74. The firm had revenue of $8.66 billion during the quarter, compared to analysts’ expectations of $8.71 billion. Sanofi had a return on equity of 25.34% and a net margin of 25.89%. The company’s quarterly revenue was down 2.3% on a year-over-year basis. Equities research analysts anticipate that Sanofi will post $3.32 earnings per share for the current fiscal year.
A number of research analysts recently weighed in on the stock. Cowen and Company restated a “market perform” rating and set a $52.00 price objective (up previously from $46.00) on shares of Sanofi in a research report on Tuesday, August 1st. BidaskClub upgraded shares of Sanofi from a “sell” rating to a “hold” rating in a research report on Saturday, August 5th. J P Morgan Chase & Co restated a “neutral” rating on shares of Sanofi in a research report on Friday, September 15th. HSBC Holdings plc upgraded shares of Sanofi from a “reduce” rating to a “hold” rating in a research report on Wednesday, August 30th. Finally, Zacks Investment Research cut shares of Sanofi from a “hold” rating to a “strong sell” rating in a report on Friday, October 6th. Two research analysts have rated the stock with a sell rating, seven have given a hold rating and four have given a buy rating to the company. The company currently has an average rating of “Hold” and an average price target of $53.50.
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.